Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)
This study is testing a new device called the Laguna Thrombectomy System to treat pulmonary embolism (blood clots in the lungs). The system includes the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System, which are designed to remove these clots. You might be able to join if you are between 18 and 85 years old, have a specific measurement of heart strain (RV/LV ratio > 0.9) from a CT scan, and meet other health criteria. The study will look at whether the device safely reduces serious problems within 48 hours after the procedure and improves heart strain. The current status of this study is unclear, and it plans to enroll 107 participants.
- Study design
- This is a multi-center study aiming to enroll 107 participants. It is testing the safety and effectiveness of the Laguna Thrombectomy System.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main results are measured within 48 hours after the procedure, or at discharge if sooner.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
At a glance
Conditions
NCT06041594
Where you'd take part
This study runs at 21 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
George Washington University
Washington D.C., District of Columbiano site contact published
Recruiting
Grandview Medical Center
Birmingham, Alabamano site contact published
Recruiting
Manatee Memorial Hospital
Bradenton, Floridano site contact published
Recruiting
Memorial Care Long Beach Medical Center
Long Beach, Californiano site contact published
Recruiting
Mission Hospital Regional Medical Center
Mission Viejo, Californiano site contact published
Recruiting
OhioHealth Research Institute
Columbus, Ohiono site contact published
Recruiting
Physicians Regional Medical Center
Naples, Floridano site contact published
Recruiting
St. Joseph Hospital of Orange
Orange, Californiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- A composite of the following major adverse events occurring within 48 (± 8) hours post-procedure:within 48 (± 8) hours post-procedure
* Device-related death within 48 (± 8) hours post-procedure * Major bleeding as defined by GUSTO (moderate or severe) within 48 (± 8) hours post-procedure. * The following treatment-related adverse events within 48 (± 8) hours post-procedure: * Cardio-respiratory deterioration, * Pulmonary vascular injury, and/or * Cardiac injury
- Reduction in RV/LV ratio from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) as assessed by Computed Tomography Angiography (CTA)from baseline to 48 (± 8) hours (or at discharge, whichever occurs first)